Lipitor peak sales 12.9 billion 2006?

Yes—Lipitor (atorvastatin) hit its sales zenith in 2006, generating about $12.9 billion worldwide in that fiscal year. That figure comes from Pfizer’s own financial reporting and independent market‑research estimates, and it marked the highest revenue for a single drug in the company’s history at the time.

Why 2006 was the peak

A quick primer on Lipitor

• Active ingredient: atorvastatin calcium (a HMG‑CoA reductase inhibitor).
• Approved: 1997 (U.S.) for lowering LDL‑cholesterol and preventing cardiovascular events.
• Market share: At its peak, it represented roughly 30 % of all statin prescriptions worldwide.
• Competition: Other statins (simvastatin, pravastatin, rosuvastatin, etc.) and, later, generics.

What happened after 2006?

• Patent landscape: Pfizer’s exclusive U.S. patent expired in 2007, allowing generics. The global patent expiration staggered through 2007‑2015.
• Generic launches: First generic atorvastatin hit U.S. shelves in late 2006, quickly capturing market share.
• Pricing pressure: Generic competition drove prices down, reducing total revenue even though prescription volumes stayed high.
• Strategic shift: Pfizer shifted focus to new indications (e.g., anti‑inflammatory, metabolic) and newer drugs.

Takeaway

The $12.9 billion figure is a well‑documented peak for Lipitor, reflecting both its clinical dominance and the timing of patent expirations. If you’re looking into the economics of blockbuster drugs, Lipitor’s trajectory is a textbook example of how rapid adoption can be followed by swift erosion once generics enter the market.